Abstract |
The development of effective microbicides for the prevention of HIV-1 sexual transmission represents a primary goal for the control of AIDS epidemics worldwide. A promising strategy is the use of bacteria belonging to the vaginal microbiota as live microbicides for the topical production of HIV-1 inhibitors. We have engineered a human vaginal isolate of Lactobacillus jensenii to secrete the anti-HIV-1 chemokine RANTES, as well as C1C5 RANTES, a mutated analogue that acts as a CCR5 antagonist and therefore is devoid of proinflammatory activity. Full-length wild-type RANTES and C1C5 RANTES secreted by L. jensenii were purified to homogeneity and shown to adopt a correctly folded conformation. Both RANTES variants were shown to inhibit HIV-1 infection in CD4(+) T cells and macrophages, displaying strong activity against HIV-1 isolates of different genetic subtypes. This work provides proof of principle for the use of L. jensenii-produced C1C5 RANTES to block HIV-1 infection of CD4(+) T cells and macrophages, setting the basis for the development of a live anti-HIV-1 microbicide targeting CCR5 in an antagonistic manner.
|
Authors | Luca Vangelista, Massimiliano Secchi, Xiaowen Liu, Angela Bachi, Letong Jia, Qiang Xu, Paolo Lusso |
Journal | Antimicrobial agents and chemotherapy
(Antimicrob Agents Chemother)
Vol. 54
Issue 7
Pg. 2994-3001
(Jul 2010)
ISSN: 1098-6596 [Electronic] United States |
PMID | 20479208
(Publication Type: Journal Article, Research Support, N.I.H., Extramural)
|
Chemical References |
- Anti-HIV Agents
- CCR5 Receptor Antagonists
- Chemokine CCL5
|
Topics |
- Anti-HIV Agents
(metabolism, pharmacology, therapeutic use)
- Blotting, Western
- CCR5 Receptor Antagonists
- Cells, Cultured
- Chemokine CCL5
(genetics, metabolism, therapeutic use)
- Chromatography, Ion Exchange
- HIV Infections
(prevention & control, virology)
- HIV-1
(drug effects)
- Humans
- Lactobacillus
(genetics, metabolism)
|